Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2021 | Metastasis | Research

Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression

Authors: Peng Wang, Haihua Zhou, Gaohua Han, Qingtao Ni, Shengbin Dai, Junxing Huang, Chunlei Dai, Lei Yu

Published in: World Journal of Surgical Oncology | Issue 1/2021

Abstract

Purpose

To assess the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma and to investigate subgroups of patients suitable for adjuvant radiotherapy.

Methods and materials

Data from 785 patients with gastric adenocarcinoma who had undergone D1/D2 radical resection and adjuvant chemotherapy were collected, the site of first progression was determined, and the relationship between the rate of local recurrence and clinicopathologic features was analyzed.

Results

By the end of the follow-up period, progression was observed in 405 patients. Local recurrence was observed as the first progression in 161 cases. The local recurrence rate was significantly lower than the non-local progression rate (20.5% vs 31.5%, p=0.007). Multivariate Cox regression analysis showed a significant relationship among degree of differentiation, T stage, N stage, and rate of local recurrence.

Conclusions

Not all patients with gastric carcinoma required adjuvant radiotherapy. However, patients with poorly differentiated cancer cells, advanced T stage (T3/T4), and positive lymph nodes, which included patients in the T4N1-2M0 subgroup, were recommended for adjuvant radiotherapy.

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro- esophageal junction. N Engl J Med. 2001;345(10):725–30. https://doi.org/10.1056/NEJMoa010187.CrossRefPubMed

Kozak KR, Moody JS. The survival impact of the intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):517–21. https://doi.org/10.1016/j.ijrobp.2007.12.029.CrossRefPubMed

Coburn NG, Guller U, Baxter NN, Kiss A, Ringash J, Swallow CJ, et al. Adjuvant therapy for resected gastric cancer–rapid,yet incomplete adoption following results of intergroup 0116 trial. Int J Radiat Oncol Biol Phys. 2008;70(4):1073–80.CrossRef

Min C, Bangalore S, Jhawar S, et al. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. Oncology. 2014;86(2):79–85. https://doi.org/10.1159/000354641.CrossRefPubMed

Liu GF, Bair RJ, Bair E, et al. Outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. PLoS One. 2014;9(1):e82642.CrossRef

Choi H, Yang SY, Cho HS, Kim W, Park EC, Han KT. Mortality differences by surgical volume among patients with stomach cancer: a threshold for a favorable volume-outcome relationship. World J Surg Onc. 2017;15(1):134. https://doi.org/10.1186/s12957-017-1203-7.CrossRef

Wang Y, Wang Y, Wu W, Lu X, An T, Jiang J. Laparoscopic gastrectomy plus D2 lymphadenectomy is as effective as open surgery in terms of long-term survival: a single-institution study on gastric cancer. World J Surg Onc. 2021;19(1):102. https://doi.org/10.1186/s12957-021-02218-1.CrossRef

Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Onc. 2016;14(1):305. https://doi.org/10.1186/s12957-016-1042-y.CrossRef

Hultman B, Gunnarsson U, Nygren P, Sundbom M, Glimelius B, Mahteme H. Prognostic factors in patients with loco-regionally advanced gastric cancer. World J Surg Onc. 2017;15(1):172. https://doi.org/10.1186/s12957-017-1243-z.CrossRef

10.

Zhang X, Zhao W, Yu Y, Qi X, Song L, Zhang C, et al. Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis. World J Surg Onc. 2020;18(1):191. https://doi.org/10.1186/s12957-020-01952-2.CrossRef

11.

Beeharry MK, Zhang TQ, Liu WT, Gang ZZ. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Onc. 2020;18(1):51. https://doi.org/10.1186/s12957-020-01819-6.CrossRef

12.

Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441–7. https://doi.org/10.1200/JCO.1993.11.8.1441.CrossRefPubMed

13.

Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63(5):1279–85. https://doi.org/10.1016/j.ijrobp.2005.05.005.CrossRefPubMed

14.

Zhang N, Fei Q, Gu J, Yin L, He X. Progress of preoperative and postoperative radiotherapy in gastric cancer. World J Surg Onc. 2018;16(1):187. https://doi.org/10.1186/s12957-018-1490-7.CrossRef

15.

Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(11):2069–77. https://doi.org/10.1200/JCO.2004.08.026.CrossRef

16.

Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4387–93.CrossRef

17.

Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer:15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49. https://doi.org/10.1016/S1470-2045(10)70070-X.CrossRefPubMed

18.

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet. 2012;379(9813):315–21. https://doi.org/10.1016/S0140-6736(11)61873-4.CrossRefPubMed

19.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20. https://doi.org/10.1056/NEJMoa072252.CrossRefPubMed

20.

Hallissey MT, Dunn AA, Ward LC, et al. The second british stomachcancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow up. Lancet. 1994;343(8909):1309–12. https://doi.org/10.1016/S0140-6736(94)92464-3.CrossRefPubMed

21.

Ml Z, Kang M, Li GC, et al. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Onc. 2016;14(1):209.CrossRef

22.

Batista TP, Mendona LM, Fassizoli-Fonte AL. The role of perioperative radio-therapy in gastric cancer. Oncol Rev. 2012;6:e23.CrossRef

23.

Lee J, Limdo H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(3):268–73. https://doi.org/10.1200/JCO.2011.39.1953.CrossRef

24.

Kim TH, Park SR, Ryu KW, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84(5):585–92.CrossRef

25.

Chen Q, Chen R, Dong Y. Inhibitory effect of endostar combined with radiotherapy on gastric cancer animal models. World J Surg Onc. 2020;18(1):165. https://doi.org/10.1186/s12957-020-01937-1.CrossRef

26.

Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2012;104(3):361–6. https://doi.org/10.1016/j.radonc.2012.08.024.CrossRef

27.

Bouvier AM, Créhange G, Azélie C, Cheynel N, Jouve JL, Bedenne L, et al. Adjuvant treatments for gastric cancer: from practice guidelines to clinical practice. Dig Liver Dis. 2014;46(1):72–5. https://doi.org/10.1016/j.dld.2013.07.003.CrossRefPubMed

28.

Zhan YQ, Li W, Sun XW, et al. Long-term efficacy of surgical treatment of gastric cancer. Chinese J Surg. 2005;43(17):1109–13.

29.

Wisbeck WM, Becher EM, Russell AH. Adenocarcinoma of the stomach:autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol. 1986;7(1):13–8. https://doi.org/10.1016/S0167-8140(86)80120-7.CrossRefPubMed

30.

Roviello F, Marrelli D, de Manzoni G, et al. Porspective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:l113–1l19.CrossRef

31.

Maehara Y, Hasuda S, Koga T, et al. Postoperative outcome and Sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2008;87:353–7.CrossRef

32.

Kan Y, Li S, Zheng Y, et al. Extensive lymph node clearance for gastric cancer l0 years experience summary. Chinese J Gen Surg. 2005;20:89–91.

33.

Ichiyoshi Y, Toda T, Minamisono Y, Nagasaki S, Yakeishi Y, Sugimachi K. Recurrence in early gastric cancer[ J]. Surgery. 1990;107(5):489–95.PubMed

34.

Sarka B, Karagol H, Gumus M, et al. Timing of death from tumor recurrence after curative gastrectomy for gastric cancer. Am J Clin Oncol. 2004;27(2):205–9.CrossRef

35.

Hartgrink HH, van de Velde CJ. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol. 2005;90(3):153–65. https://doi.org/10.1002/jso.20222.CrossRefPubMed

36.

Brenner RM, Kivity S, Kundel Y, Purim O, Peled N, Idelevich E, et al. Ethnic variation in toxicity and outcome of adjuvant chemoradiation for gastric cancer in Israel. Anticancer Res. 2013;33(11):5151–7.PubMed

Title: Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression
Authors: Peng Wang
Haihua Zhou
Gaohua Han
Qingtao Ni
Shengbin Dai
Junxing Huang
Chunlei Dai
Lei Yu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Gastric Cancer
Radiotherapy
Gastric Cancer
Cytostatic Therapy
Published in: World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-021-02304-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression

Abstract

Purpose

Methods and materials

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods and materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Differentiation of primary lung cancer from solitary lung metastasis in patients with colorectal cancer: a retrospective cohort study

An abdominal-sacral approach with preoperative embolisation for vulvar solitary fibrous tumour: a case report

Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment

miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1

Clinicopathological features and risk factors analysis of lymph node metastasis and long-term prognosis in patients with synchronous multiple gastric cancer

Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment